Comparison of quinupristin/dalfopristin with standard therapies for the treatment of complicated skin and soft tissue infections due to gram-positive pathogens: Results of two open, randomized multicenter studies;Vergleich von quinupristin-dalfopristin mit standardtherapien zur behandlung komplizierter haut-und weichteilinfektionen durch grampositive erreger

Chemotherapie Journal, Supplement

Volumn 9, Issue 19, 2000, Pages 63-68

  Wacha, H ^a   Forster H ^a  

^a Hospital zum heiligen Geist   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; DALFOPRISTIN PLUS QUINUPRISTIN; OXACILLIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; ERYSIPELAS; GRAM POSITIVE BACTERIUM; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SKIN INFECTION; SOFT TISSUE INFECTION; WOUND INFECTION;

EID: 0034453051     PISSN: 09446486     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (4)

1. Susceptibility to RPR 106,972, quinupristin/dalfopristin and erythromycin among recent clinical isolates of enterococci, staphylococci and streptococci from North American medical centers
2. Randomized, comparative, multicenter, open study of quinupristin/dalfopristin (Q/D, Synercid®) versus standard therapy (Cefazolin or Vancomycin) in the treatment of complicated Gram-positive skin and skin structure infections (C-SSSI)
3. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin
4. Randomized, comparative, multi-center, open study of quinupristin/dalfopristin (Q/D, RP 59500, Synercid®) versus standard therapy (Oxacillin or Vancomycin) in the treatment of complicated Gram-positive skin and skin structure infections (C-SSSI)